Nifty Pharma | Market Views & Discussions

Nifty Pharma

The index in one line: India’s medicine makers in one basket: the largest listed pharmaceutical companies, from generics to ingredient suppliers.

Objective

To track India’s pharmaceutical sector through its largest listed drugmakers. It covers companies that make finished medicines as well as those that supply active ingredients. Hospitals and diagnostics are left out, so it is a pure drug-manufacturing view.

Universe and constituent selection

Nifty 500 pharmaceutical stocks that traded on at least 90% of days over six months. The top 20 by free-float market cap are chosen, with preference for derivatives-segment stocks. Non-F&O stocks that hit their price band on 20% or more of days are excluded.

Weighting methodology

Free-float market cap, capped at 33% per stock and 62% for the top three at each rebalance. As of 30 Sep 2026, Sun Pharma leads at 19.51%. The top three, including Divi’s and Laurus Labs, make up about 39%.

Review and rebalancing

Semi-annual, using data for the six months ending 31 January or 31 July. Changes take effect at the end of March and September, with four weeks’ notice. A stock can leave if it slips in rank or falls short on trading frequency.

What makes this index different

It is narrower than Nifty Healthcare and Nifty500 Healthcare, which also hold hospitals. Weight is spread fairly evenly after Sun Pharma: five companies sit between about 7% and 12%. That makes it less dependent on one name than many sector indices.

What it helps you analyse

Drug exports, US generic pricing and regulatory inspections. Many constituents earn a large share of revenue abroad, so the rupee-dollar rate also matters. Comparing it with Nifty Healthcare shows whether drugmakers or care providers are driving the sector.

Can I invest in it?

Yes, through an ETF that tracks it. Futures & options are not available. It holds only drugmakers, so consider a broader healthcare product as well if you also want direct exposure to hospitals and diagnostics.

A useful way to read it

:black_small_square: Export-heavy drugmakers often react to US regulatory news more than to India’s economy.

:black_small_square: Sun Pharma’s results matter most, as it was 19.51% of the index as of 30 Sep 2026.

:black_small_square: Compare it with Nifty Healthcare to see whether hospitals are adding to or holding back the sector.

Sector allocation

Company weights shown are the top 10 constituents, with the rest grouped as Others. They are the latest available snapshot (date shown on the image) and can change with market movement and index reviews.